As the numbers of physicians specializing in infectious diseases continues to fall short of need, nearly two-thirds of Americans live in areas with little or no access to an infectious diseases specialist, according to a study published online today in the Annals of Internal Medicine.
The incomprehensible death of George Floyd has left our country grieving and demands attention to the environment of disparities, inequities and structural racism in which it occurred. As infectious diseases and HIV health care providers, we stand against discrimination in any form.
Meeting requested to address questions, inform planning for use of remdesivir, the only FDA-authorized drug for COVID-19 treatment.
H.R.6800, the Health Heroes Act, includes policies and investments that would bolster the federal response to COVID-19, increase testing capacity and availability of medical supplies and address the disparate impact of COVID-19 on vulnerable populations.
The U.S. Department of Health and Human Services decision allowing state health departments to distribute limited supplies of remdesivir to treat COVID-19 where they are needed will support fair and equitable access to the drug.
Strong and specific federal guidance is critical to protecting our country, our communities, our health and our lives in the face of the still escalating impacts of COVID-19 across the United States.
With FDA emergency authorization of remdesivir to treat COVID-19, the Infectious Diseases Society of America and its HIV Medicine Association are calling on Vice President Mike Pence and other administration officials to provide public transparency in the process for determining how and where the medication is distributed
Sepsis, a complication of infection that can cause low blood pressure (shock) as well as lung, kidney, and organ failure, affects an estimated 1.7 million adults each year in the U.S. and contributes to 270,000 deaths.
The Infectious Diseases Society of America has released 15 recommendations to assist clinicians, laboratory personnel and policy makers in decisions on the use of SARS-CoV-2 diagnostic testing for people with and without symptoms of COVID-19.
With data showing alarmingly high rates of COVID-19 infection among people who are incarcerated, the Infectious Diseases Society of America and its HIV Medicine Association today released policy recommendations to prevent and respond to the spread of the coronavirus in detention settings.
As leading public health and medical organizations, we represent front-line workers and experts who are witnessing the critical importance of maintaining physical distancing measures until data and resources indicate that lifting them is safe.
The Infectious Diseases Society of America has released eight recommendations on the use of personal protective equipment (PPE) for infection prevention among health care personnel caring for patients with suspected or confirmed COVID-19.